RECURSION PHARMACEUTICALS, INC. Increase (Decrease) in Other Accrued Liabilities
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Increase (Decrease) in Other Accrued Liabilities of -$12.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2026-06-30 was $5.83M, a 48.78% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2026-03-31 was -$18.45M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2025-12-31 was $15.84M, a 50.56% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2025-09-30 was -$8.03M, a 226.52% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2025 was -$7.41M, a 234.21% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2024 was $5.52M, a 17.86% decline from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2023 was $6.72M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2022 was -$576.00K, a 104.51% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 3 month as first filed | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$12.62M 10-Q · filed 2026-08-05 | $3.22M derived: sum of 3 quarters · filed 2026-08-05 | -$4.82M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$18.45M 10-Q · filed 2026-05-06 | -$2.61M derived: sum of 2 quarters · filed 2026-05-06 | -$10.64M derived: sum of 3 quarters · filed 2026-05-06 | $733.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $15.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.81M derived: sum of 2 quarters · filed 2026-02-25 | $19.18M derived: sum of 3 quarters · filed 2026-08-05 | -$7.41M 10-K · filed 2026-02-25 | |
| 2025-09-30 | -$8.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.35M derived: sum of 2 quarters · filed 2026-08-05 | -$23.25M 10-Q · filed 2025-11-05 | -$12.73M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $11.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$15.21M 10-Q · filed 2026-08-05 | -$4.69M derived: sum of 3 quarters · filed 2026-08-05 | $1.66M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$26.59M 10-Q · filed 2026-05-06 | -$16.07M derived: sum of 2 quarters · filed 2026-05-06 | -$9.72M derived: sum of 3 quarters · filed 2026-05-06 | -$2.21M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $10.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $16.87M derived: sum of 2 quarters · filed 2026-02-25 | $24.38M derived: sum of 3 quarters · filed 2026-02-25 | $5.52M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $6.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.86M derived: sum of 2 quarters · filed 2025-11-05 | -$5.00M 10-Q · filed 2025-11-05 | -$2.22M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $7.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$11.35M 10-Q · filed 2025-08-05 | -$8.57M derived: sum of 3 quarters · filed 2026-02-25 | -$988.00K derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | -$18.86M 10-Q · filed 2025-05-05 | -$16.07M derived: sum of 2 quarters · filed 2026-02-25 | -$8.49M derived: sum of 3 quarters · filed 2026-02-25 | -$2.29M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $10.36M derived: sum of 2 quarters · filed 2026-02-25 | $16.57M derived: sum of 3 quarters · filed 2026-02-25 | $6.72M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $7.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $13.78M derived: sum of 2 quarters · filed 2024-11-06 | $3.94M 10-Q · filed 2024-11-06 | $16.10M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | $6.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.64M 10-Q · filed 2024-08-08 | $8.52M derived: sum of 3 quarters · filed 2025-02-28 | $10.61M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | -$9.85M 10-Q · filed 2024-05-09 | $2.32M derived: sum of 2 quarters · filed 2025-02-28 | $4.41M derived: sum of 3 quarters · filed 2025-02-28 | $5.48M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | $12.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $14.26M derived: sum of 2 quarters · filed 2025-02-28 | $15.33M derived: sum of 3 quarters · filed 2025-02-28 | -$576.00K 10-K · filed 2025-02-28 | |
| 2022-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.16M derived: sum of 2 quarters · filed 2023-11-09 | -$12.74M 10-Q · filed 2023-11-09 | -$11.10M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$14.83M 10-Q · filed 2023-08-08 | -$13.19M derived: sum of 3 quarters · filed 2024-02-29 | -$3.07M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | -$15.90M 10-Q · filed 2023-05-08 | -$14.26M derived: sum of 2 quarters · filed 2024-02-29 | -$4.14M derived: sum of 3 quarters · filed 2024-02-29 | -$3.00M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $11.77M derived: sum of 2 quarters · filed 2024-02-29 | $12.90M derived: sum of 3 quarters · filed 2024-02-29 | $12.76M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $10.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $11.26M derived: sum of 2 quarters · filed 2022-11-08 | $11.12M 10-Q · filed 2022-11-08 | $14.25M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $997.00K 10-Q · filed 2022-08-09 | $4.12M derived: sum of 3 quarters · filed 2023-02-27 | $4.93M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | -$135.00K 10-Q · filed 2022-05-10 | $1.13M 10-Q · filed 2021-05-12 | $2.99M derived: sum of 2 quarters · filed 2023-02-27 | $3.80M derived: sum of 3 quarters · filed 2023-02-27 | $5.78M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $3.93M derived: sum of 2 quarters · filed 2023-02-27 | $5.92M derived: sum of 3 quarters · filed 2023-02-27 | $4.12M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $806.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.79M derived: sum of 2 quarters · filed 2021-11-10 | $996.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $190.00K 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | -$1.79M 10-Q · filed 2021-05-12 | ||||
| 2019-12-31 | -$798.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |